Brexafemme (Ibrexafungerp Citrate) Patent Expiration, LOE Window & CMS Spending

Brexafemme (Ibrexafungerp Citrate) by GSK: FDA Orange Book core substance LOE 2035-01-19 (last listed 2039-06-10), 0 AB generics, $18K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGSK
FDA Application & PathwayN214900 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2035-01-19
Last Listed Patent or Exclusivity Date2039-06-10
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$18K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$18K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for GSK across sibling Meru public-data platforms.